GHpVac enjoys exclusive, worldwide commercialization rights to HpVac-R13 and its variants from the University of Zurich.
See also the following granted patents: WO2015/114575 and WO2015/144576.
In the course of her studies on gastric cancer, Prof. Dr. Anne Müller and her team have confirmed that HpVac-R13 has a tolerogenic effect sufficient to confer protection against several inflammatory or allergic diseases.
